Prudential Financial Inc vs Sanofi SA — how do they compare? Prudential Financial Inc trades at $118.18 (market cap $40.97B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 2.6× Prudential Financial Inc's market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| PRU | SNY | |
|---|---|---|
Market Cap | $40.97B | $104.85B |
Sector | Financials | Health |
52-Week High | $119.07 | $52.34 |
52-Week Low | $92.00 | $41.33 |
Enterprise Value | $68.03B | $121.38B |
Dividend Yield | 4.75% | 5.53% |
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $118.59, down 0.4% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates solid fundamentals with a P/E of 12.15, net income margin of 5.5%, and consistent earnings beats in recent quarters. Recent business developments include expanding retirement offerings and international growth initiatives, supported by strong cash flow generation of $6.27B from operations in 2025.
PRU presents a compelling value opportunity with attractive valuation metrics and steady profitability, though analyst sentiment remains cautious with 68% hold ratings. Key risks include significant investing outflows and debt levels, while catalysts include upcoming Q2 earnings and continued retirement market expansion. The stock trades above consensus price targets, suggesting limited near-term upside potential despite fundamental strength.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →